Resolvyx Pharmaceuticals
Boston, Massachusetts, USA
Team Members:
Jean-Francois Formela
Sector:
Life Sciences
Sub-Sector:
Therapeutics
http://www.resolvyx.com
Close
Resolvyx is a biopharmaceutical company committed to the discovery and development of therapies based on the novel concept of inflammation resolution through activation of the body’s own off-switch mechanisms.
In the News:
Resolvyx and Collaborators Publish Study Showing Potential of Neuroprotectin D1 (NPD1) To Treat Neovascular Eye Disease
Resolvyx Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials
Resolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome
Resolvyx Initiates Phase I Clinical Trial of Novel Resolvin, RX-10001, for Asthma and Inflammatory Diseases
Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting
Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting
Resolvyx Announces Completion of FDA Review Period for Dry Eye Drug
Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediators of Inflammatory Disease
FierceBiotech Names Resolvyx Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008
